The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds

NCT01113307 | Completed

• 1 other identifier: MC-103
• Study Type: observational
• Target: 131
• Locations: 1 country
• Sites: 7

Brief Summary

The primary objective of the study is to define procedures for the use of CureXcellTM in the community through Clalit Health Services. Secondary objective is to evaluate the blinding method in a subgroup of patients, which will be used in a future study named: a multinational, multi-center, randomized, double blind, placebo controlled study for the evaluation of the tolerability, safety and efficacy of CureXcell™ therapy plus adequate ulcer treatment, in diabetic patients with ulcers in the lower extremities. Adults with chronic ulcers; pressure ulcers, venous ulcers, diabetic foot ulcers or post operative ulcer will be recruited to the study. Patients that have been recruited for the study will be treated as required for their medical condition. As required, cultures will be taken, IV or PO antibiotics will be given and debridement will be carried out. Patients will be referred to catheterization, revascularization, or amputation as required and the decision to do so will not be affected in any way by the study. CureXcellTM will be used as adjunct treatment to good ulcer care (GUC).

Conditions

Wounds

Keywords

Chronic ulcers; pressure ulcers; venous ulcers; diabetic foot ulcers; post operative ulcers; hard to heal ulcers

Outcome Measures

Primary Outcomes (1)

• Proportion of patients with complete wound closure

  Week 24

Secondary Outcomes (3)

• Median time to complete wound closure

  End of study

• Change in wound area between Baseline and Last Observation

  End of study

• Rate of wound infections, cellulitis, and osteomyelitis

  End of study

Study Arms (1)

Hard to heal wounds

Biological: Activated allogeneic white blood cells

Interventions

Activated allogeneic white blood cells BIOLOGICAL

The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).

Also known as: CureXcell

Hard to heal wounds

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with chronic ulcers; pressure ulcers, venous ulcers, diabetic foot ulcers or post operative ulcers.

You may qualify if:

• Patients between 18 and 90 years of age with one ulcer that has not shown signs of normal healing (according to physician experienced in wound therapy) for more than 3 weeks
• The patient suffers from diabetic ulcer, decubitus ulcer, venous insufficiency ulcer and post operative wound.
• In patients with suspected malnutrition albumin \> 2.5 g/dL in blood tests performed within the last three weeks.
• Patients with adequate blood perfusion: palpated distal pulses TP or DP or if not palpable, arterial pressures during rest ABI \> 0.6.
• Patients without edema over +2 (patient's edema must be controlled by medical and/or bandaging or lympha press).
• Use of elastic bandaging in wounds due to venous insufficiency (when there is no involvement of an arterial problem).
• Wound condition does not immediately jeopardize the extremity.
• The patient's life is not at risk (for any reason).
• The Patient has a life expectancy of at least one year.
• Women of childbearing potential must be willing to use reliable methods of birth control.
• Willing and able to sign an informed consent form and attend the follow up according to the treating staff instructions until complete wound closure.
• A patient suffering from diabetes and a chronic ulcer in the lower extremity (ankle and below) and is CureXcell™ -naive.
• Signing an appendix to the consent form for the 'treatment blinding guessing test'.

You may not qualify if:

• More than one wound;
• Inadequately treated recurrent pressure components in the wound. If required, ulcer will be treated with preliminary treatment for local pressure components (shoes and even cast or wheel chair for the treatment period)
• Neoplastic ulcer
• A patient with active malignant disease during the last five years, except for a patient suffering from adequately treated Basal Cell Carcinoma which does not present in the wound area.
• Sepsis
• Confirmed osteomyelitis
• Patients suffering from significant immunosuppression.
• INR \> 3 in patients receiving anticoagulation drugs, in blood tests performed within two weeks prior to the first injection
• A response to previous blood infusions (in case administered)
• Patient receiving unique blood components (radiated, washed etc.)
• Pregnant patient
• Wounds for more than a year
• A fistula/cavity which anatomical shape does not enable a direct injection into the wound
• A patient participating in another clinical trial, or who participated in another clinical trial within the last 30 days.

Sponsors & Collaborators

• Macrocure Ltd.: lead

Study Sites (7)

Omer Clalit Clinic

Afula, Israel

Location

Sold Clalit Clinic

Beersheba, Israel

Location

Hamoshava Diabetic Wound Clinic

Jerusalem, Israel

Location

Ramat Eshcol Wound Clinic

Jerusalem, Israel

Location

Zvulun Wound Clinic

Kiryat Bialik, Israel

Location

Hasharon Medical Center

Petah Tikva, Israel

Location

Zamenhoff Wound Clinic

Tel Aviv, Israel

Location

MeSH Terms

Conditions

Wounds and Injuries; Pressure Ulcer; Varicose Ulcer; Diabetic Foot

Condition Hierarchy (Ancestors)

Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases; Varicose Veins; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Diabetic Angiopathies; Foot Ulcer; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies

Study Officials

• Ram Avrahami, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• David Snir, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• Yibgeni Sherman, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• David Vigoda, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• Dimitri Gimelreich, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• Asher Corcos, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

• Laios Kazir, MD

  Clalit Health Services

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2010
• First Posted: April 29, 2010
• Study Start: May 1, 2010
• Primary Completion: July 1, 2011
• Study Completion: September 1, 2011
• Last Updated: January 31, 2013

Record last verified: 2013-01

Locations

IL (7)